Get to know our clinical trials
Phase 2, adaptive, clinical trial to evaluate the efficacy of intracoronary infusion of AB-1002 in adult subjects with NYHA functional class III heart failure and GenePHIT
THE AIM OF THE ASK-CHF2-CS201 CLINICAL TRIAL IS TO EVALUATE THE SAFETY AND EFFICACY OF AB-1002 FOR THE TREATMENT OF PATIENTS WITH HEART FAILURE AND NON-ISCHEMIC CARDIOMYOPATHY.
Status
In recruitment
headquarters
Pamplona
Early phase
Technical Summary
- PHASE 2, ADAPTIVE, DOUBLE-MASKED, PLACEBO-CONTROLLED, RANDOMIZED, MULTICENTER, DOUBLE-BLINDED TRIAL TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF INTRACORONARY INFUSION OF AB-1002 IN ADULT SUBJECTS WITH NYHA (NEW YORK HEART ASSOCIATION) FUNCTIONAL CLASS III HEART FAILURE AND NON-ISCHEMIC CARDIOMYOPATHY (GENEPHIT)
- Code EudraCT: 2024-510581-17-00
- Protocol number: ASK-CHF2-CS201
- Promoter: Bayer
- Molecule/Drug: AB-1002
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.